Abbott Laboratories (ABT)Storebrand Asset Management AS added to its stake +91K shares
Storebrand Asset Management AS added to its stake in Abbott Laboratories, per its Q2 2026 13F.
- 2.86M
- Shares reported · +91K vs prior quarter
- 0.64%
- Disclosed portfolio weight
- $259M
- Reported value
- Holdings as of
- Jun 30, 2026
- Filed
- Aug 12, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Mar 27, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
- May 7, 2026Insider · Their largest buy since 2019Director purchased ~$174K of ABT shares in the open market
- Jun 12, 2026Congress · 1 personMembers of Congress: 2 purchases
- Jun 16, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
- Jun 17, 2026FDAFDA device clearance: Amplatzer TorqVue Exchange System
- Jul 2, 2026FDAFDA device clearance: Amplatzer TorqVue LP Delivery System; Amplatzer TorqVue LP Catheter
- Jul 7, 2026Government · Federal Register proposed ruleMedicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; Including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data; Prior Authorization; Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor Act (EMTALA); and Notices of Closure of Teaching Hospitals and Opportunities To Apply for Available Slots
- Jul 8, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
- Jul 14, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
- Jul 15, 2026FDAFDA device clearance: EnSite X EP System
- Jul 16, 2026Company filing · Form 8-K · ResultsReported its results
- Jul 17, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
- Jul 30, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
- Aug 6, 2026Government · Federal Register noticeForeign-Trade Zone (FTZ) 39, Notification of Proposed Production Activity; Abbott Laboratories; (Diagnostic Medical Devices); Irving, Texas
- Aug 11, 2026InsiderOfficer sold ~$643K of ABT shares in the open market
What came next
- Aug 25, 2026Insider · 1 personInsiders: 2 sales (~$46.2M)
- Sep 2, 2026InsiderOfficer sold ~$3K of ABT shares in the open market
- Sep 17, 2026FDAFDA device clearance: EnSite X EP System
- Sep 23, 2026FDAFDA device clearance: Anti-HCV Next
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Abbott Laboratories
For Abbott Laboratories, OQRO holds 5 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 82 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABT page.
How this filing works
Other disclosures at Abbott Laboratories
- SEC Form 4Sep 3, 2026
- SEC Form 144Sep 2, 2026
- SEC Form 4Aug 27, 2026
- SEC Form 4Aug 27, 2026
- SEC Form 13F-HRAug 26, 2026
- SEC Form 13F-HRAug 20, 2026
Everything OQRO holds on this company is on its ABT page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
